Related Experiment Video
Updated: Aug 20, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Learn-confirm in model-informed drug development: Assessing an immunogenicity quantitative systems pharmacology
Linnea C Franssen1, Maciej J Swat2, Andrzej M Kierzek2,3
1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
Predicting immunogenicity of therapeutic proteins is challenging. The Immunogenicity Simulator, developed using trial data, shows credibility for assessing drug development risks.
Area of Science:
- Biopharmaceutical Development
- Immunology
- Drug Safety
Background:
- Immunogenicity against therapeutic proteins can lead to drug attrition, impacting pharmacokinetics, pharmacodynamics, efficacy, and safety.
- Predicting immunogenicity is complex due to multifactorial drivers including compound properties, subject characteristics, and treatment parameters.
Purpose of the Study:
- To assess the credibility of the Immunogenicity Simulator for predicting therapeutic protein immunogenicity.
- To evaluate the simulator's utility during the drug development process.
Main Methods:
- Developed the Immunogenicity Simulator using published, predominantly late-stage trial data from 15 therapeutic proteins.
- Conducted a single-blinded evaluation using subject-level data from 10 additional monoclonal antibodies.
Main Results:
- The Immunogenicity Simulator demonstrated credibility in its assessment.
- The evaluation provides insights into the simulator's applicability in drug development.
Conclusions:
- The Immunogenicity Simulator is a credible tool for assessing immunogenicity risks during drug development.
- This tool can aid in mitigating potential attrition caused by immunogenicity.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
08:47Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Quantitative Aspects of Drug-Receptor Interaction
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Physiological Models